Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + tislelizumab + lenvatinib + carvedilol
- Development stage
- Unknown
- Lead developer
- Tongji Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Intra-arterial
01
Overview
This quadruple therapy regimen combines Transarterial Chemoembolization (TACE) with the PD-1 inhibitor tislelizumab, the multi-kinase inhibitor lenvatinib, and the non-selective beta-blocker carvedilol. It is specifically designed for patients with unresectable hepatocellular carcinoma (HCC) and concurrent cirrhotic portal hypertension. Tislelizumab enhances the immune response against tumor cells by blocking the PD-1/PD-L1 pathway. Lenvatinib inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor growth, including VEGFR and FGFR. Carvedilol is used to manage portal hypertension and may potentially modulate the tumor microenvironment to enhance immunotherapy efficacy. TACE provides localized tumor control through embolization and chemotherapy.
- Other names
- TACE Combined With Tislelizumab, Lenvatinib, and CarvedilolQuadruple therapy for HCC with portal hypertension
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)ADRA1A (α1A)ADRB2 (β2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)ADRB1 (β1)
Beyond the preview
Go deeper on TACE + tislelizumab + lenvatinib + carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + tislelizumab + lenvatinib + carvedilol.